Clinical Trials · NCT06784752
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 240
- Start date
- May 2025
- Locations
- 65 sites, 12 countries
- Primary endpoint
- Progression Free Survival (PFS) centrally assessed by Blinded Independent Review Committee (BIRC)